Update: a Novel Stratification of Myelofibrosis Patients by Likelihood of Response to JAK2 Inhibitors

Current prognostic models for MF (e.g. DIPSS plus) have uncertain value in predicting clinical response or survival during treatment with JAK2 inhibitors.

Source: Clinical Lymphoma, Myeloma and Leukemia - August 26, 2016 Category: Hematology Authors: Kamal Menghrajani, Philip Boonstra, Alissa Weber, Cecelia Perkins, Krisstina Gowin, Huong (Marie) Nguyen, Ruben Mesa, Jason Gotlib, Moshe Talpaz Source Type: research